Yale biologist Brandon Ogbunu recalls the time he spent studying gene regulation in Susan Gottesman’s lab at NCI.
Full story at National Cancer Institute
All in National Cancer Institute
Yale biologist Brandon Ogbunu recalls the time he spent studying gene regulation in Susan Gottesman’s lab at NCI.
Full story at National Cancer Institute
Experimental treatment is designed to target Kaposi sarcoma tumors as well as to counter the immune-dampening effects of the virus that causes them.
Full story at National Cancer Institute
A potential therapy for COVID-19 binds to a viral enzyme that SARS-CoV-2 requires for replication.
Full story at National Cancer Institute
PARP inhibitors, used to treat tumors whose cells have problems repairing damaged DNA, become ineffective when cancer cells lose the DNA-modifying enzyme TET2.
Full story at National Cancer Institute
Chemoimmunotherapy can lead to long-lasting remissions of HIV-associated primary central nervous system lymphoma, without impairing cognitive function.
Full story at National Cancer Institute
A new genetic analysis can assign patients with diffuse large B-cell lymphoma to one of seven different genetic subtypes of the disease.
Full story at National Cancer Institute
Analyzing tumors for a particular molecular signature could help clinicians assess whether someone with melanoma is likely to benefit from immunotherapy.
Full story at National Cancer Institute
Lymphoma trial demonstrates how fine-tuning CAR design can improve immunotherapy outcomes.
Full story at National Cancer Institute
HDAC inhibitors are best known for their ability to turn genes on. But certain gene networks shut down in their presence, suggesting a new treatment strategy for cancer.
Full story at National Cancer Institute